Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 21925 W Field Pkwy Ste 235 DEER PARK IL 60010-7278 |
Tel: | N/A |
Website: | https://etonpharma.com |
IR: | See website |
Key People | ||
Sean E. Brynjelsen President, Chief Executive Officer, Director | James R. Gruber Chief Financial Officer, Treasurer, Company Secretary | David C. Krempa Chief Business Officer |
Business Overview |
Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria. |
Financial Overview |
For the fiscal year ended 31 December 2023, Eton Pharmaceuticals Inc revenues increased 49% to $31.6M. Net loss decreased 90% to $936K. Revenues reflect Product sales increase from $11.3M to $26.1M. Lower net loss reflects Developing and commercializing prescription drug products segment loss decrease of 86% to $1.2M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.36 to -$0.04. |
Employees: | 30 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $72.10M as of Mar 31, 2024 |
Annual revenue (TTM): | $31.64M as of Mar 31, 2024 |
EBITDA (TTM): | -$0.29M as of Mar 31, 2024 |
Net annual income (TTM): | -$0.94M as of Mar 31, 2024 |
Free cash flow (TTM): | $6.04M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 25,688,062 as of Mar 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |